Results 101 to 110 of about 670,718 (407)

Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer

Molecular Oncology, EarlyView.
We used whole exome and RNA‐sequencing to profile divergent genomic and transcriptomic landscapes of microsatellite stable (MSS) and microsatellite instable (MSI) colorectal cancer. Alterations were classified using a computational score for integrative cancer variant annotation and prioritization.
Efstathios‐Iason Vlachavas, Konstantinos Voutetakis, Vivian Kosmidou, Spyridon Tsikalakis, Spyridon Roditis, Konstantinos Pateas, Ryangguk Kim, Kymberleigh Pagel, Stephan Wolf, Gregor Warsow, Antonia Dimitrakopoulou‐Strauss, Georgios N. Zografos, Alexander Pintzas, Johannes Betge, Olga Papadodima, Stefan Wiemann   +15 more
wiley   +1 more source

Research of the best screen interval for middle aged and elderly Chinese males with baseline prostate specific antigen levels <2.0 ng/mL in prostate cancer screening [PDF]

Journal of Men's Health
This study aimed to investigate the optimal screening interval of a prostate specific antigen (PSA) screening program for men aged 40–70 with a baseline PSA 10 ng/mL, or 4–10 ng/mL (gray area) and f/t PSA
Yu Chen, Gansheng Xie, Gang Li, Yu Li
doaj   +1 more source

Integrating influenza antigenic dynamics with molecular evolution [PDF]

arXiv, 2013
Influenza viruses undergo continual antigenic evolution allowing mutant viruses to evade host immunity acquired to previous virus strains. Antigenic phenotype is often assessed through pairwise measurement of cross-reactivity between influenza strains using the hemagglutination inhibition (HI) assay.
arxiv  

A stochastic individual-based model to explore the role of spatial interactions and antigen recognition in the immune response against solid tumours [PDF]

, 2019
Spatial interactions between cancer and immune cells, as well as the recognition of tumour antigens by cells of the immune system, play a key role in the immune response against solid tumours. The existing mathematical models generally focus only on one of these key aspects.
arxiv   +1 more source

Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
We aggregated a cohort of 1012 mCRPC tissue samples from 769 patients and investigated the association of gene expression‐based pathways with clinical outcomes. Loss of AR signaling, high proliferation, and a glycolytic phenotype were independently prognostic for poor outcomes, and an adverse transcriptional feature score incorporating these pathways ...
Marina N. Sharifi, Eric Feng, Nicholas R. Rydzewski, Amy K. Taylor, Jamie M. Sperger, Yue Shi, Kyle T. Helzer, Matthew L. Bootsma, Viridiana Carreno, Alex H. Chang, Luke A. Nunamaker, Grace C. Blitzer, Tianfu Andy Shang, Aishwarya Subramanian, Anders Bjartell, Andreas Josefsson, Pernilla Wikström, Emily Feng, Manish Kohli, Rendong Yang, Scott M. Dehm, Eric J. Small, Rahul Aggarwal, David A. Quigley, Joshua M. Lang, Shuang G. Zhao, Martin Sjöström   +26 more
wiley   +1 more source

TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis

Molecular Oncology, EarlyView.
TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam, Megan E. Roche, Zhao Lin, Diana Whitaker‐Menezes, Victor Diaz‐Barros, Eurico Serrano, Maria Paula Martinez Cantarin, Nancy J. Philp, Atrayee Basu Mallick, Ubaldo Martinez‐Outschoorn   +9 more
wiley   +1 more source

The end of the road for prostate specific antigen testing? [PDF]

, 2013
Many candidate biomarkers for diagnosis of prostate cancer have been investigated, but prostate‑specific antigen (PSA) testing remains the frontline test for both mass screening and individual clinical testing.
Nna, E
core   +2 more sources

Dynamics-based peptide-MHC binding optimization by a convolutional variational autoencoder: a use-case model for CASTELO [PDF]

arXiv, 2020
An unsolved challenge in the development of antigen specific immunotherapies is determining the optimal antigens to target. Comprehension of antigen-MHC binding is paramount towards achieving this goal. Here, we present CASTELO, a combined machine learning-molecular dynamics (ML-MD) approach to design novel antigens of increased MHC binding affinity ...
arxiv  

Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time [PDF]

Journal of Urology, 2008
Prostate specific antigen is a glycoprotein found almost exclusively in normal and neoplastic prostate cells. Prostate specific antigen doubling time, or the change in prostate specific antigen over time, has emerged as a useful predictive marker for assessing disease outcome in patients with prostate cancer. It is important to agree on definitions and
Anthony V. D'Amico, Andrew G. Lee, Fernando J. Bianco, Oliver Sartor, Philip M. Arlen, James L. Gulley, Michael W. Kattan, Philip W. Kantoff, William D. Figg, Stephen J. Freedland, Meredith M. Regan, William L. Dahut   +11 more
openaire   +3 more sources

The roles and applications of extracellular vesicles in cancer

Molecular Oncology, EarlyView.
Extracellular vesicles (EVs) are minute versions of cells limited by a lipid bilayer containing cytoplasm from the cell that releases them, but without a nucleus and thus unable to self‐reproduce. EVs contain multiple molecules (proteins, lipids, glycans, and nucleic acids) they can induce complex responses in cells.
Clotilde Théry, Daniel Louvard
wiley   +1 more source